Telecoms.com Intelligence's Annual Industry Survey Highlights Increasing Importance Of 'Designed-For' B2B BSS Solutions
16.12.2019 12:00:00 EET | Business Wire | Press release
MDS Global Ltd, a leading BSS-as-a-Service provider, in collaboration with Telecoms.com Intelligence, today announced the findings of their 2019 Annual Industry Survey Report. In the report, dedicated and designed-for modern B2B BSS solutions were highlighted as a key requirement by Communication Service Providers (CSPs), with 84% of respondents identifying B2B as the area where enterprise customers will generate the highest revenue growth in 2020 and beyond.
Based on 540 responses to a survey, the report took an overview of the industry landscape over the last 12 months and provided projections for activity from 2020 and beyond. The OSS/BSS section of the survey highlighted that the B2B segments, including large enterprises (30%), small- and medium-sized enterprises (SMEs) (19%), small office/home office (SOHO) (17%), as well as public sector and wholesale partners, need to be served by a specialist B2B BSS platform. This platform should offer a dedicated digital engagement approach supporting personalised order, workflow and service management demands of enterprises, resellers and partners.
According to the survey, 50% of CSPs already have a separate platform to reflect this sector's demand, and 50% of these require a more digital approach to market engagement. 90% of CSPs agreed that the SME segment specifically requires real-time usage and control and the ability to configure, price and order services via online tools. Defined by service level agreements, business customers often demand higher levels of customisation, shorter time to market for new services, and tend to be less tolerant of failures. But at the same time, they are also less sensitive to price, compared with the consumer market.
Flexibility and customisation for both CSPs and enterprise is also especially important in 5G with its strong virtualisation and software-centric characteristics. The B2B sector is forecast to significantly outweigh the B2C sector as a major source of revenue from 5G services and the report reinforced how important 5G technology is in shaping and scheduling future projects. A staggering 97% of CSPs will use SDN/NFV environments to allow integrated services to be personalised, demonstrating that virtualisation will trigger major BSS change.
Gary Bunney, CEO, MDS Global said, "Currently, most BSS running in Communication Service Providers are hardwired to support traditional enterprise services and incorporate many offline business processes that require high-cost specialist resources to deliver constant change."
He continues, "Today’s market demands low-cost service agility. MDS Global is uniquely placed to assist CSPs in automating service engagement whilst enabling the opportunity that 5G and service personalisation brings to enterprises. We provide a dedicated B2B BSS-as-a-Service platform, decreasing the costs associated with operations, automating customer engagement and providing agility to ensure our CSP customers are able to invent, tailor and launch new services without the hindrance of engineering challenges."
MDS Global's B2B-on-Demand enables cost-efficiency and dedicated service delivery. Download the Telecoms.com Insight 2019 Annual Industry Survey here.
About MDS Global
MDS Global, a leading BSS-as-a-Service provider of VNO, B2B and IoT solutions, look after all aspects of monetisation, assurance and customer steering for complex products and services. We offer a digital operating model in a DevOps context, which enhances stakeholder experiences and provides unprecedented business agility.
Headquartered in the UK, MDS Global’s customers include BT Enterprise (UK), eir (Ireland), iD Mobile from Dixons Carphone (UK), TalkTalk (UK), Telefónica (UK), Vodafone (Germany, Greece and NL), Orange (Belgium), KPN (Netherlands) and Telia (Denmark).
For further information: www.mdsglobal.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191216005010/en/
Contact information
Martine Naughton
MDS Global
Email: martine.naughton@mdsglobal.com
Tel: +44 (0) 7909 475815
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
